Drug intelligence / Profile preview

[18F]FIDT-10b

Development stage: Phase 2
Lead developer: Peking Union Medical College Hospital
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration: Intravenous

Overview

[18F]FIDT-10b is a fluorine-18 labeled positron emission tomography (PET) imaging agent being developed by Peking Union Medical College Hospital. It is designed to specifically target and identify involved myocardium in patients with cardiac amyloidosis, including transthyretin cardiac amyloidosis (ATTR-CA) and light chain cardiac amyloidosis (AL-CA). The agent is currently being evaluated in a Phase 1/2 clinical trial to assess its safety, biodistribution, dosimetry, and diagnostic performance in healthy subjects and patients with cardiac amyloidosis.

Other names: 18F-FIDT-10bfluorine-18 labeled FIDT-10bfluorine18 labeled FIDT-10bfluorine 18 labeled FIDT-10b

Beyond the preview

Go deeper on [18F]FIDT-10b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]FIDT-10b.